Han Jian-Ping, Sun Shu-Li, Li Ren-Zhong, Zhang Fu-Sheng, Wang Shi-Chang, Cheng Jun, Deng Yun-Feng, Wang Yan, Yu Chun-Bao
Shandong Anti-tuberculosis Center, Jinan 250013, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2003 Feb;26(2):70-3.
To analyze the treatment outcomes in patients with smear positive tuberculosis, and to compare the difference in treatment response among patients infected with drug-sensitive and drug-resistant strains.
From 1998 to 2000, seven hundred and seventy-seven patients with primary smear-positive tuberculosis, which were from 30 surveillance sites, were followed for two years to monitor their treatment outcomes.
At the completion of the 6 months' therapy, the overall rate of treatment failure was 1.8%, 2.6% for the drug-resistant cases and 1.6% for the drug-sensitive cases. Six-month follow-up showed a positive conversion rate of 2.7% in all the cases, 8.5% and 1.2% (P < 0.005) in the drug-resistant and the drug-sensitive cases respectively. One year follow-up showed that the positive conversion rate was 2.6% in all the cases, 6.9% and 1.6% (P < 0.005) in the drug-resistant and the drug-sensitive cases, respectively. Two-year follow-up showed an overall positive conversion rate of 1.3%, 1.0% and 1.3% in the drug-resistant and the drug-sensitive cases, respectively. Of the 152 drug-resistant cases, the rate of treatment failure was 2.6% at the completion of 6 months' therapy, but in cases with MDR-TB the rate was 10.3%. Six-month follow-up showed an overall positive conversion rate of 8.5%, but the rate reached 37.0% in cases with MDR-TB. One-year and two-year follow-up showed that the positive conversion rates were 6.9% and 1.0% respectively in all the drug-resistant cases, but 6.3% and 6.7% respectively in the MDR cases.
Under the guidelines of the National Tuberculosis Program (NTP), the 2H(3)R(3)S(3)Z(3)/4H(3)R(3) regimen for primary smear-positive pulmonary TB was effective. But the cure rate was lower and the positive conversion rate higher in patients with MDR-TB.
分析涂片阳性肺结核患者的治疗结果，并比较感染敏感菌株和耐药菌株患者在治疗反应上的差异。
1998年至2000年，对来自30个监测点的777例原发性涂片阳性肺结核患者进行了为期两年的随访，以监测其治疗结果。
在6个月治疗结束时，总体治疗失败率为1.8%，耐药病例为2.6%，敏感病例为1.6%。6个月随访显示，所有病例的痰菌阴转率为2.7%，耐药病例为8.5%，敏感病例为1.2%（P<0.005）。1年随访显示，所有病例的痰菌阴转率为2.6%，耐药病例为6.9%，敏感病例为1.6%（P<0.005）。2年随访显示，总体痰菌阴转率为1.3%，耐药病例和敏感病例分别为1.0%和1.3%。在152例耐药病例中，6个月治疗结束时治疗失败率为2.6%，但耐多药结核病病例的失败率为10.3%。6个月随访显示总体痰菌阴转率为8.5%，但耐多药结核病病例的阴转率达到37.0%。1年和2年随访显示，所有耐药病例的痰菌阴转率分别为6.9%和1.0%，但耐多药病例分别为6.3%和6.7%。
在国家结核病规划（NTP）的指导下，2H(3)R(3)S(3)Z(3)/4H(3)R(3)方案对原发性涂片阳性肺结核有效。但耐多药结核病患者的治愈率较低，痰菌阴转率较高。
Zotero 插件